Ингибиторы тирозинкиназы EGFR в лечении метастазов немелкоклеточного рака легкого EGFRm в головном мозге
https://doi.org/10.17650/1726-9784-2018-17-2-22-30
Аннотация
В структуре метастатического поражения головного мозга рак легкого занимает первое место. В обзоре представлены методы лечения метастатического поражения головного мозга при немелкоклеточном раке легкого: от локальных методов лечения (облучение всего головного мозга, стереотаксическая радиохирургия и хирургия опухолей центральной нервной системы) до системной противоопухолевой лекарственной терапии с акцентом на новые таргетные препараты (ингибиторы EGFR), которые показали высокую эффективность при метастазах немелкоклеточного рака легкого в центральную нервную систему.
Об авторах
Д. Р. Насхлеташвили
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
Давид Романович Насхлеташвили
115478 Москва, Каширское шоссе, 24
В. А. Горбунова
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
М. Б. Бычков
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
А. Х. Бекяшев
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
В. Б. Карахан
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
В. А. Алешин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
Е. А. Москвина
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
Список литературы
1. Wen P.Y., Black P.M., Loeffler J.S. Cancer: Principles and Practice of Oncology (6th ed.). In: Metastatic Brain Cancer. Philadelphia, PA: Lippincott WIlliams & Wilkins, 2001. P. 2655–2670.
2. Tabouret E., Chinot O., Metellus P. et al. Recent trends in associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(5):339–46. DOI: 10.1093/jnci/dji055. PMID: 15741570.
3. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129–39. DOI: 10.1056/NEJMoa040938 PMID: 15118073.
4. D’Antonio C., Passaro A., Gori B. et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 2014;6(3):101–14. DOI: 10.1177/1758834014521110. PMID: 24790650.
5. Han G., Bi J., Tan W. et al. A retrospective analysis in patients with EGFR-mu tantlung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 2016;7(35):56998–7010. DOI: 10.18632/oncotarget.10933. PMID: 27486770.
6. Stanic K., Zwitter M., Hitij N.T. et al. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014;48(2):173–83. DOI: 10.2478/raon-2014-0016. PMID: 24991207.
7. Rangachari D., Yamaguchi N., Vander-Laan P.A. et al. Brain metastases in patients with EGFR-mutated or ALK-re-arranged non-small-cell lung cancers. Lung Cancer 2015;88(1):108–11. DOI: 10.1016/j.lungcan.2015.01.020. PMID: 25682925.
8. Langer C.J., Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23(25):6207–19.
9. Schouten L.J., Rutten J., Huveneers H.A. et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698– 705. PMID: 12173339.
10. Tabouret E., Chinot O., Metellus P. et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012;32:4655–62. PMID: 23155227.
11. Sundstrom J.T., Minn H., Lertola K.K., Nordman E. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 1998;30:296–9. PMID: 9677016.
12. Besse B., Le Moulec S., Sénéllard H. et al. A phase II trial of bevazicumab in combination with first-line chemotherapy or second-line erlotinib in nonsquamous NSCLC patients with asymptomatic untreated brain metastases. Ann Oncol 2012;23:9. Abstr 1299.
13. Gaspar L., Scott C. Rotman L. et al. Recursive partitioning analysis (RPA) of prognostic factors in there Radiation Therapy Oncology Groups (RTOG) brain metastases trials. Int. J. Radiat Oncol Biol Phys. 1997;43:745–51. DOI: 10.1016/S0360-3016(96)00619-0.
14. NCCN Guidelines. Портал национальной всеобщей онкологической сети nccn.org. [Электронный ресурс] 25.01.18 version 2.2018-december 19, 2017. URL: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
15. Горбунова В.А., Артамонова Е.В., Бредер В.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2017. URL: https://rosoncoweb.ru/standarts/RUSSCO/2017/recoms2017_01.pdf.
16. Minotti V., Crino L., Meacci M.L. et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in nonsmall cell lung cancer. Lung Cancer 1998;20:93–8. PMID: 9711527.
17. Kelly K., Bunn Jr P.A. Is it time to reevaluate our approach to the treatment of brain metastases in patients with nonsmall cell lung cancer? Clin Cancer 1998;20:85–91. PMID: 9711526.
18. Besse B., Le Moulec S., Mazières J. et al. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res 2015;21(8):1896–903. DOI: 10.1158/1078-0432.CCR-14-2082. PMID: 25614446.
19. Poon A.N., Ho S.S., Yeo W., Mok T.S. Brain metastasis responding to gefitinib alone. Oncology 2004;67(2):174–8. DOI: 10.1159/000081005. PMID: 15539923.
20. Cappuzzo F., Calandidi C., Bartolini S., Crinò L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003;89:246–7. DOI: 10.1038/sj.bjc.6601116. PMID: 12865910.
21. Gurpide A., Perez-Gracia J.L. et al. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer. Two case reports and review of the literature. Clin Lung Cancer 2005;7(2): 138–40.
22. Namba Y., Kijima T., Yokota S. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004;6(2):123–8. DOI: 10.3816/CLC.2004.n.026. PMID: 15476598.
23. Kim K., Lee D.H., Lee J. et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations. J Clin Oncol 2011;suppl 29;abstr 7606.
24. Li Z., Lu J., Zhao Y. et al. The retrospec tive analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. J Clin Oncol 2011;suppl 29;abstr e18065.
25. Iuchi T., Shingyoji M., Sakaida T. et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;82(2):282–7. DOI: 10.1016/j.lungcan.2013.08.016. PMID: 24021541.
26. Kim J.E., Lee D.H., Choi Y. et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009;65(3):351–4. DOI: 10.1016/j.lung-can.2008.12.011. PMID: 19157632.
27. Weber B., Winterdahl M., Memon A. et al. Erlotinib accumulation in brain metastases from non-small cell lung can cer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6(7):1287–9. DOI: 10.1097/JTO.0b013e318219ab87. PMID: 21847041.
28. Elmeliegy M.A., Carcaboso A.M., Tagen M. et al. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation Clin Cancer Res 2011;17(1):89–99. DOI: 10.1158/1078-0432.CCR-10-1934. PMID: 21088257.
29. Kitazaki T., Oka M., Nakamura Y. et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005;49(3):337–43. DOI: 10.1016/j.lungcan.2005.03.035. PMID: 15955594.
30. Togashi Y., Masago K., Fukudo M. et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950–5. DOI: 10.1097/JTO.0b013e3181e2138b. PMID: 20479691.
31. Wakeling A.E., Guy S.P., Woodburn J.R. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62(20):5749–54. PMID:12384534.
32. Naskhletashvili D.R., Gorbounova V. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in the treatment of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). 37th ESMO Congress, Austria, Vienna, 28 September – 2 October 2012. Abstr 1330.
33. Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б. и др. Гефитиниб («Иресса») в лечении метастазов немелкоклеточного рака легкого в головном мозге. Опухоли головы и шеи 2012;3:63–5. [Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B. et al. Gefitinib (Iressa) in treatment of brain metastases of non-small cell lung cancer. Opucholi golovy i shei = Head and Neck Tumors 2012;3:63–5. (In Russ.)].
34. Yang J.C., Wu Y.L., Schuler M. et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. DOI: 10.1016/S1470-2045(14)71173–8. PMID: 25589191.
35. Schuler M, Wu YL, Hirsh V. et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol 2016;11(3):380–90. DOI: 10.1016/j.jtho.2015.11.014. PMID: 26823294.
36. Chinnaiyan P., Huang S., Vallabhane ni G. et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328–35. DOI: 10.1158/0008-5472.CAN-04-3547. PMID: 15833866.
37. Akimoto T., Hunter N.R., Buchmiller L. et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884–90. PMID: 10537357.
38. Qin D., Ma J., Xiao J. et al. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol 1997;20:263–5.
39. Qin D., Ou G., Mo H. et al. Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys 2001;51:959–62. PMID: 11704317.
40. DeAngelis L.M., Delattre J.Y., Posner J.B. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789–96. PMID: 2725874.
41. Ma S., Xu Y., Deng Q. et al. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese popula tion. Lung Cancer 2009;65:198–203.
42. Welsh J.W., Komaki R., Amini A. et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013;31:895–902. DOI: 10.1200/JCO.2011.40.1174. PMID: 23341526.
43. Magnuson W.J., Lester-Coll N.H., Wu A.J. et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol 2017;35(10):1070-1077. DOI: 10.1200/JCO.2016.69.7144. PMID: 28113019.
44. Ballard P., Yates J.W.T., Yang Zh. et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 2016;22(20):130–40.DOI:10.1158/1078-0432.CCR-16-0399.
45. Kobayashi S., Boggon T.J., Dayaram T. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92. DOI: 10.1056/NEJMoa044238. PMID: 15728811.
46. Yun C.H., Mengwasser K.E., Toms A.V. et al. The T790M mutation in EGFR ki nase causes drug resistance by increasing theaffinity for ATP. Proc Natl Acad Sci USA 2008;105:2070–5. DOI: 10.1073/pnas.0709662105. PMID: 18227510.
47. Cross D.A., Ashton S.E., Ghiorghiu S. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046–61. DOI: 10.1158/2159-8290.CD-14-0337. PMID: 24893891.
48. Ramalingam S., Yang J.C., Lee C.K. et al. Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. J Thorac Oncol 2016;11:152.
49. Yang J., Ramalingam S.S., Jänne P.A. et al. LBA2_ PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016;11:152–3.
50. Kim D., Yang J., Cross D. et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant nonsmall cell lung cancer (NSCLC) brain metastases (BM). Ann Oncol 2014;25:iv146–64.
51. Ahn M.J., Tsai C.M., Yang J.C. et al. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from Phase II studies. Eur J Cancer 2015;51:625–6.
52. Mok T.S., Wu Y.-L., Ahn M.-J. et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;376:629–40.
53. Wu Y-L., Jenkins S., Ramalingam S.S. et al. Osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctD-NA analysis [abstract and oral presentation]. Presented at: World Conference on Lung Cancer; December 4–7, 2016; Vienna, Austria. J Thorac Oncol 2017;12(Suppl 1):386. Abstr MA08.03.
54. Mok T., Ahn M.-J., Han J.-Y. et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3) [abstr and oral presentation]. Presented at: American Society of Clinical Oncology Congress; 2–6 June 2017; Chicago, IL. J Clin Oncol 2017;35(Suppl). Abst 9005.
55. Vansteenkiste J., Reungwetwattana T., Nakagawa K. et al. LBA5 CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Ann Oncol 2017;28(Issue suppl 10) 1 https://doi.org/10.1093/annonc/mdx729.007
56. Berghoff A.S., Preusser M. The future of targeted therapies for brain metastases. Future Oncol 2015;11:2315–27.
57. Venur V.A., Ahluwalia M.S. Targeted therapy in brain metastases: Ready for primetime? Am Soc Clin Oncol Educ Book 2016;35:e123–30. DOI: 10.14694/EDBK_100006. PMID: 27249714.
Рецензия
Для цитирования:
Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б., Бекяшев А.Х., Карахан В.Б., Алешин В.А., Москвина Е.А. Ингибиторы тирозинкиназы EGFR в лечении метастазов немелкоклеточного рака легкого EGFRm в головном мозге. Российский биотерапевтический журнал. 2018;17(2):22-30. https://doi.org/10.17650/1726-9784-2018-17-2-22-30
For citation:
Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B., Bekyashev A.Kh., Karakhan V.B., Aleshin V.A., Moskvina E.A. EGFR Tyrosine kinase inhibitors in the treatment of metastases of non-small cell lung cancer in the brain. Russian Journal of Biotherapy. 2018;17(2):22-30. (In Russ.) https://doi.org/10.17650/1726-9784-2018-17-2-22-30
Просмотров:
537
Послать статью по эл. почте 
